1354690-24-6 leniolisib

Proprjetajiet

Dehra bajda għal solidu kristallin abjad barra
Temp tal-Ħażna. Aħżen fi -20 grad
Solubilità DMF: PBS (pH 7.2) (1: 1): {0. 5 (max conc. mg / ml); 1.11 (max conc. mm)
DMSO: 71.67 (Max Conc. Mg / mL); 159.09 (Max Conc. Mm)
Etanol: 16.5 (max conc. Mg / ml); 36.63 (max conc. Mm)

 

Applikazzjoni:

Leniolisib (CDZ173) huwa inibitur selettiv PI3K δ żviluppat minn Pharming u liċenzjat minn Novartis. Jintuża prinċipalment biex jikkura sindromu ta 'attivazzjoni żejda PI3K δ (APDs) f'adolexxenti u adulti ta '12 -il sena' l fuq, u ġie approvat għall-kummerċjalizzazzjoni mill-FDA tal-Istati Uniti fl-24 ta 'Marzu, 2023

 

Sinonimi:

Leniolisib

1354690-24-6

CDZ173 Bażi Ħieles

Cdz -173 bażi ħielsa

Cdz 173- nx

Leniolisibum

Cdz -173- nx

CDZ173

Bażi ħielsa mill-leniolisib

(S) -1- (3- (({6- (6- methoxy -5-} (trifluoromethyl) pyridin -3- yl) {6}}}, 6,7, {{{9} } tetrahydropyrido [4, 3- d] pyrimidin -4- yl) amino) pyrrolidin -1- yl) propan -1- wieħed

1- [(3s) -3- [[{6- [{6- methoxy -5- (trifluoromethyl) pyridin -3- yl] -7}}, {8- dih ydro -5 h-pyrido [4, 3- d] pyrimidin -4- yl] amino] pyrrolidin -1- yl] propan {-1- wieħed

Cdz -173

1- propanone, 1- ((3s) -3- ((5,6,7, 8- tetrahydro -6- ({6- metoxy -5- (trifluoromethyl ) -3- piridinyl) pirido (4, 3- d) pyrimidin -4- yl) amino) -1- pyrrolidinyl) - -

1- ((3s) -3- (({6- ({6- methoxy -5- (trifluoromethyl) pyrimidin -3- yl) -5}}}, 6,7, {{{{{{{{{{{{{1 0}} tetrahydropyrido (4, 3- d) pyrimidin -4- yl) amino) pyrrolidin -1- yl) propan -1- wieħed

 

 

It-tags Popolari: 1354690-24-6 leniolisib, iċ-Ċina 1354690-24-6 manifatturi tal-leniolisib, fornituri